Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy | Zendy

Andrew J. Stephenson | Zendy; Peter T. Scardino | Zendy; Michael W. Kattan | Zendy; Thomas M. Pisansky | Zendy; Kevin M. Slawin | Zendy; Eric A. Klein | Zendy; Mitchell S. Anscher | Zendy; Jeff M. Michalski | Zendy; Howard M. Sandler | Zendy; Daniel W. Lin | Zendy; Jeffrey D. Forman | Zendy; Michael J. Zeléfsky | Zendy; Larry L. Kestin | Zendy; Claus G. Roehrborn | Zendy; Charles Catton | Zendy; Theodore L. DeWeese | Zendy; Stanley L. Liauw | Zendy; Richard K. Valicenti | Zendy; Deborah A. Kuban | Zendy; Alan Pollack | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy

Author(s) -

Andrew J. Stephenson,

Peter T. Scardino,

Michael W. Kattan,

Thomas M. Pisansky,

Kevin M. Slawin,

Eric A. Klein,

Mitchell S. Anscher,

Jeff M. Michalski,

Howard M. Sandler,

Daniel W. Lin,

Jeffrey D. Forman,

Michael J. Zeléfsky,

Larry L. Kestin,

Claus G. Roehrborn,

Charles Catton,

Theodore L. DeWeese,

Stanley L. Liauw,

Richard K. Valicenti,

Deborah A. Kuban,

Alan Pollack

Publication year - 2007

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2006.08.9607

Subject(s) - medicine , prostatectomy , nomogram , prostate cancer , androgen deprivation therapy , urology , biochemical recurrence , prostate specific antigen , radiation therapy , proportional hazards model , concordance , cancer , surgery , oncology

An increasing serum prostate-specific antigen (PSA) level is the initial sign of recurrent prostate cancer among patients treated with radical prostatectomy. Salvage radiation therapy (SRT) may eradicate locally recurrent cancer, but studies to distinguish local from systemic recurrence lack adequate sensitivity and specificity. We developed a nomogram to predict the probability of cancer control at 6 years after SRT for PSA-defined recurrence.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research